What is Kodiak Sciences?
Headquartered in Palo Alto, California, Kodiak Sciences is a clinical-stage biopharmaceutical enterprise dedicated to the research, development, and commercialization of transformative therapeutics for retinal diseases. The company utilizes its unique Antibody Biopolymer Conjugate (ABC) platform to engineer potent, durable, and effective treatments. Its lead candidate, tarcocimab tedromer (KSI-301), represents a significant advancement in anti-VEGF therapy, currently undergoing rigorous Phase IIb/III clinical evaluation. Beyond its primary focus, the company is expanding its research into bispecific conjugates like KSI-501 and KSI-101, which target both pro-inflammatory cytokines and VEGF to address complex retinal inflammatory conditions. This multi-faceted approach to drug discovery highlights the company's commitment to addressing the underlying pathology of vision-threatening disorders.
How much funding has Kodiak Sciences raised?
Kodiak Sciences has raised a total of $476.4M across 6 funding rounds:
Other Financing Round
$1.8M
Series B
$34M
Debt
$33M
Stock Offering
$90M
Stock Offering
$317.4M
Debt
$150K
Other Financing Round (2009): $1.8M with participation from Undisclosed
Series B (2016): $34M led by Undisclosed
Debt (2018): $33M supported by Perceptive Advisors and ArrowMark Partners
Stock Issuance/Offering (2018): $90M featuring Undisclosed
Stock Issuance/Offering (2019): $317.4M backed by Undisclosed
Debt (2020): $150K with participation from PPP
Key Investors in Kodiak Sciences
Perceptive Advisors
A New York-based investment firm managing significant assets, specializing in providing capital to innovative healthcare and life sciences technologies.
ArrowMark Partners
An investment management firm focused on identifying growth opportunities across various sectors, including healthcare and specialized life sciences.
Undisclosed Investors
What's next for Kodiak Sciences?
With the recent capital injection, Kodiak Sciences is well-positioned to execute its late-stage clinical development strategy. The primary focus remains the successful completion of ongoing Phase III trials for tarcocimab tedromer, which is critical for future regulatory submissions and potential market entry. Furthermore, the company is expected to prioritize the advancement of its preclinical pipeline, specifically the bispecific protein candidates designed to tackle inflammatory retinal pathways. As the firm transitions from a research-heavy entity to a potential commercial-stage organization, the strategic deployment of these funds will be instrumental in scaling manufacturing capabilities and preparing for global market access. Investors will be closely monitoring clinical data readouts, as these results will serve as the primary catalyst for the company's long-term valuation and market leadership in the ophthalmology space.
See full Kodiak Sciences company page
